Research programme: pain therapeutics - Axxam

Drug Profile

Research programme: pain therapeutics - Axxam

Alternative Names: BKR1 antagonist - Axxam; CB2 agonist - Axxam; Nav 1.7 blocker - Axxam; TRPM8 blocker - Axxam

Latest Information Update: 02 Feb 2011

Price : $50

At a glance

  • Originator Axxam; Newron Pharmaceuticals; Primm srl; University of Milan Bicocca
  • Developer Axxam; Newron Pharmaceuticals
  • Class
  • Mechanism of Action Bradykinin B1 receptor antagonists; Cannabinoid receptor CB2 agonists; Nav1.7-voltage-gated-sodium-channel-inhibitors; Purinergic P2X7 receptor antagonists; TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Pain

Most Recent Events

  • 02 Feb 2011 Early research is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top